Genetic Signatures Limited (ASX:GSS)


right-arrow Created with Sketch. -0.08 (-6.02%)
MCAP $178.8M
Last trade 16.10pm 28/01/2022 20mins delayed

Latest Announcements

28/01/2022GSSGenetic Signatures Limited
21/01/2022 Price SensitivePSGSSGenetic Signatures Limited
20/01/2022GSSGenetic Signatures Limited
10/01/2022 Price SensitivePSGSSGenetic Signatures Limited
21/12/2021 Price SensitivePSGSSGenetic Signatures Limited
22/11/2021GSSGenetic Signatures Limited
22/11/2021GSSGenetic Signatures Limited
22/11/2021GSSGenetic Signatures Limited

Company Overview

Genetic Signatures Limited is an Australia-based molecular diagnostics company. The Company is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. It also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.

GSS in the news

Australia’s Therapeutic Goods Administration (TGA) registers a saliva-based protocol for testing samples…
Genetic Signatures (GSS) has released a wide-ranging update, revealing it’s expecting $21…
Genetic Signatures (GSS) has signed a supply agreement for its COVID-19 detection…
Healthcare stock Genetic Signatures (GSS) has boosted its preliminary sales figures ahead…

Search Previous Announcements